Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tracon Pharma (NQ: TCON )

0.5780 +0.0010 (+0.17%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tracon Pharma

TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update
From Runway Growth Finance Corp.
Via GlobeNewswire
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update
From Runway Growth Finance Corp.
Via GlobeNewswire
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
Initial $3.5M Funding Maintains Cash Runway of Mid-2023 
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update
From Runway Growth Finance Corp.
Via GlobeNewswire
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned
Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter 
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Clinical Stage Trials, Novel Targeted Cancer Therapeutics and $25.6 Million in the Bank to Persevere this NASDAQ through 2023: TRACON Pharmaceuticals (NASDAQ: TCON)
Via Get News
25.6 Million in cash will Bankroll this NASDAQ until 2023; Capitol Efficient Clinical Stage, Novel Targeted Cancer Therapeutics: TRACON Pharmaceuticals (NASDAQ: TCON)
Via Get News
Capital Efficient: Clinical Stage NASDAQ Company – Novel Targeted Cancer Therapeutics Company: TRACON Pharmaceuticals (NASDAQ: TCON)
Via Get News
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at TRACON Pharmaceuticals, Inc. 
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.